Biofrontera Inc. Warrants financials
$0.0135−32.50%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $10.1M | $17.1M | $7.0M | $9.0M | $8.6M | $12.6M | $9.0M | $7.8M | $7.9M | $10.6M | $8.9M |
| Gross profit | $9.6M | $8.0M | $14.1M | $4.9M | $6.4M | $5.3M | $7.3M | $4.1M | $3.5M | $3.8M | $5.2M | $4.3M |
| Gross margin | 79.9% | 79.0% | 82.4% | 70.7% | 70.7% | 61.9% | 58.0% | 45.9% | 44.6% | 48.0% | 49.3% | 48.4% |
| Operating income | -$524.0K | -$4.3M | $4.6M | -$6.3M | -$5.1M | -$4.5M | -$1.7M | -$5.0M | -$5.1M | -$5.5M | -$3.9M | -$4.6M |
| Net income | -$604.0K | -$4.8M | $5.6M | -$6.6M | -$5.3M | -$4.2M | -$1.4M | -$5.7M | -$257.0K | -$10.4M | $3.5M | -$6.3M |
| Net margin | −5.0% | −47.1% | 33.0% | −95.1% | −59.0% | −48.9% | −11.1% | −62.9% | −3.3% | −131.9% | 33.3% | −71.3% |
| Diluted EPS | $-0.05 | $-0.41 | $0.48 | $-0.62 | $-0.57 | $-0.47 | $-0.18 | $-0.98 | $-0.05 | $-2.88 | $1.66 | $-4.64 |
| EBITDA | -$459.0K | -$4.3M | $4.6M | -$6.3M | -$5.1M | -$4.5M | -$1.7M | -$4.8M | -$4.9M | -$5.3M | -$3.8M | -$4.3M |
| Operating cash flow | -$1.7M | -$70.0K | -$2.4M | -$3.8M | -$3.0M | -$4.1M | -$1.0M | -$1.2M | -$4.7M | -$3.3M | -$8.8M | -$2.1M |
| Free cash flow | -$1.7M | -$75.0K | -$2.4M | -$3.8M | -$3.0M | -$4.1M | -$1.1M | -$1.2M | -$4.7M | -$3.4M | -$8.8M | -$2.1M |
| Diluted shares | 12.9M | 11.7M | 11.7M | 10.8M | 9.4M | 8.9M | 7.6M | 5.8M | 5.1M | 3.6M | 2.1M | 1.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.7M | $6.3M | $6.4M | $3.4M | $7.2M | $1.8M |
| Short-term investments | $8.0K | $9.0K | $9.0K | $10.0K | $9.0K | $7.0K |
| Total debt | $4.6M | $4.7M | $4.6M | $4.5M | $4.3M | $4.2M |
| Total assets | $24.1M | $24.8M | $28.6M | $15.4M | $20.1M | $16.6M |
| Total liabilities | $18.1M | $18.7M | $18.1M | $18.0M | $24.8M | $16.1M |
| Shareholders' equity | $6.0M | $6.1M | $10.5M | -$2.6M | -$4.7M | $469.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology